美国FDA正式认定NMN可作为膳食补充剂合法使用

Core Insights - The FDA has officially confirmed the legality of NMN (β-nicotinamide mononucleotide) as a dietary supplement, marking a significant development in the health technology sector [1] - The previous indecision by the FDA in 2022 had delayed the promotion of NMN in the U.S. market, despite its safety and widespread use in other regions like Canada, Japan, and Hong Kong [1] - NMN is recognized for its role as a precursor to NAD+ (nicotinamide adenine dinucleotide), showing benefits such as improved bodily functions, reduced cardiovascular disease risk, and enhanced metabolism in human clinical studies [1] - The W+duanlta brand, developed by a team led by Nobel Prize winner Werner Arber, targets the 30-50 age group, particularly those with high-stress jobs and poor sleep quality, offering tailored anti-aging solutions [2] Industry Summary - The FDA's recent decision is expected to revitalize the NMN market, providing a favorable environment for brands like W+duanlta to thrive [2] - W+duanlta stands out as the only brand achieving "full score" across all dimensions, meeting FDA GMP certifications and passing 208 tests for safety and quality [2] - The brand's formulation has been optimized over three years to cater specifically to the needs of Chinese consumers, addressing common issues such as energy decline and stress [2]